Contraline: Funding, Investors & Team (Oct 2026)
Contraline is a medical device company that has developed a proprietary injectable hydrogel platform for use in reproductive and contraceptive applications. Contraline's first product, Adam, is implanted into the vas deferens through a minimally invasive, outpatient procedure and once implanted, the gel effectively blocks sperm. Adam is non-hormonal, designed to last years, and easily reversible.
Contraline has raised $110M across 3 funding rounds on record, the most recent a Series B of $92.5M announced in Jun 2026.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Contraline Company Profile and Key Stats
Latest funding round on record: Jun 2026.
Contraline Funding Rounds
Contraline raised $10.7M in a Series A announced in Oct 2021.
1.1 years later, a Series A of $7.2M was announced in Nov 2022.
3.6 years later, a Series B of $92.5M was announced in Jun 2026.
Contraline Founders and Leadership Team
Contact details for the Contraline team: 1 of 1 has an email address on file.
Start 14-day free trial →Contraline Funding Compared to Other Biotechnology Startups
Contraline's latest round of $92.5M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Contraline in Biotechnology and Charlottesville
Companies Similar to Contraline
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Contraline Funding FAQs
What does Contraline do?
Contraline is a medical device company that has developed a proprietary injectable hydrogel platform for use in reproductive and contraceptive applications. Contraline's first product, Adam, is implanted into the vas deferens through a minimally invasive, outpatient procedure and once implanted, the gel effectively blocks sperm. Adam is non-hormonal, designed to last years, and easily reversible.
How much funding has Contraline raised?
Contraline has raised $110M across 3 rounds on record. The most recent is a Series B of $92.5M announced in Jun 2026.
When did Contraline last raise funding?
Contraline's most recent funding round on record is a Series B of $92.5M, announced in Jun 2026.
Who is the CEO of Contraline?
Kevin Eisenfrats is listed as CEO at Contraline.
Where is Contraline headquartered?
Contraline is based in Charlottesville, Virginia, United States.
How many employees does Contraline have?
Contraline is in the 11-50 employee band.
How does Contraline's funding compare to other Biotechnology startups?
Contraline's latest round of $92.5M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Contraline Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Contraline is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.